Loading... Please wait...

Blog

CellMosaic to exhibit at the AACR annual meeting 2019

Posted

Come visit us at Booth 4622 close to the entrance of the Exhibition Hall, meet our experts to find out about more recent developments in bioconjugation at CellMosaic and learn about how our bioconjugation solutions will help you in your research and drug development. Featured topics include CellMosaic’s:

  • Personalized antibody-drug conjugation kits to help in ADC development
  • Proprietary super-hydrophilic AqueaTether™ (AqT™) linkers for drug conjugation, delivery, and diagnostic research
  • AqueaTether™ linker-based conjugation kits and products
  • Other personalized conjugation kits
  • Custom bioconjugation services


Date: March 29-April 3, 2019

Location: Georgia World Congress Center, Atlanta, Georgia, USA

Exhibit Show Dates and Times:

Sunday, March 31, 1 – 5 pm

Monday, April 1, 9 am – 5 pm

Tuesday, April 2, 9 am – 5 pm

Wednesday, April 3, 9 am – 5 pm 


About CellMosaic, Inc.

CellMosaic, Inc. is an innovator and leader in bioconjugation and crosslinking technologies. Several key technologies are being developed at CellMosaic, including oxLink technologies for studying protein–protein interactions; NeIon™ technologies for detecting and quantitating trace amounts of analytes of interest; super-hydrophilic AqueaTether linkers for clean conjugation of antibody/protein/peptide/oligo with small molecule drugs; biocompatible, biodegradable, mono-dispersed AqueaTether macromolecules for modification of protein/peptide/oligo drugs and preparation of highly loaded small molecule drugs for better delivery; and bioconjugation platform technologies involving screening, labeling/crosslinking, purification, and analysis of any bioconjugate. The company is also actively engaged in serving biological communities by providing custom synthesis of high quality bioconjugate products.

About AqueaTether Therapeutics.

AqueaTether Therapeutics is a division of CellMosaic, created in 2016. AqueaTether™ Therapeutics focuses on the discovery and development of novel hybrid drug entities beyond the conventional drug classes by using AqueaTether ™ (AqT™) conjugation and delivery platform technologies. We work together with our partners to advance their program. For more information regarding AqueaTether-based bioconjugate drugs, please visit our website: www.aqttherapeutics.com

CellMosaic to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

Woburn, MA, April 11, 2018 – CellMosaic is going to present our work on developing water soluble AqueaTether™ (AqT™) carriers for Drug Conjugation and Delivery at the upcoming AACR meeting at McCormick Place in Chicago, Illinois. Please come and visit us during the poster session. We are currently looking for partners who can further develop and utilize [...]

Read More »


CellMosaic Inc. received Notice of Allowance on AqueaTether™ (AqT™) molecules from the Japanese Intellectual Property Office

Woburn, MA, Nov. 8th, 2017 – CellMosaic announced today that the Japanese IP Office issued a formal Notice of Allowance for a patent on AqueaTether (AqT™) molecules (Application No. 2014-521744 entitled “Novel crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof”). Upon issuance, the patent will provide intellectual property protection for a broad range of AqT™ molecules constructed from sugar [...]

Read More »


CellMosaic Inc. received Notice of Allowance on AqueaTether™ (AqT™) molecules from the Australian Intellectual Property Office

Woburn, MA, Nov. 1st, 2017 – CellMosaic announced today that the Australian Government IP Office issued a formal Notice of Allowance for a patent on AqueaTether (AqT™) molecules (Application No. 2012284055 entitled “Novel crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof”). Upon issuance, the patent will provide intellectual property protection for a broad range of AqT™ molecules constructed from [...]

Read More »


CellMosaic®, Inc. received Notice of Allowance from USPTO for another patent on AqueaTether™ (AqT™) molecules

Woburn, MA, Oct. 27, 2017 – CellMosaic announced today that the United States Patent and Trademark Office (USPTO) issued a formal Notice of Allowance for another patent on AqueaTether (AqT™) molecules (Application No. 15/281,023 entitled “Novel crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof”). This patent will provide intellectual property protection for AqT™ molecules constructed from monomeric sugar alcohols or [...]

Read More »


CellMosaic®, Inc. receives Notice of Allowance from USPTO on reversible oxime photocrosslinking reagent (oxLink™) molecules for studying protein-protein interactions

Woburn, MA, March 5, 2017 – CellMosaic® announced today that the United States Patent and Trademark Office (USPTO) issued a formal patent Notice of Allowance on reversible oxime photocrosslinking reagent (oxLink™) molecules (Patent Application No. 14/965,699 entitled “Crosslinking reagents, methods, and compositions for studying protein-protein interactions”). Protein-protein interactions play an important role in regulating physiological functions in cells, such as gene [...]

Read More »


CellMosaic, Inc. received Notice of Allowance on AqueaTether™ (AqT™) molecules from the Chinese Intellectual Property Office.

Woburn, MA, Feb. 23, 2017 – CellMosaic® announced today that the Chinese Intellectual Property Office issued a formal Notice of Allowance for a patent on AqueaTether (AqT™) molecules (Chinese Patent Application No. 201280034231.3 entitled “Sugar alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof”). The issued patent will provide intellectual property protection in China for broad coverage of AqT™ molecules [...]

Read More »


CellMosaic, Inc. Spins Out AqueaTether™ Technology into Separate Division, AqueaTether Therapeutics.

Woburn, MA, Feb. 13, 2017 – CellMosaic announces that it has formed a separate division to support development and commercialization of its proprietary AqueaTether™ (AqT™) technologies. The new entity will control and manage the technology and intellectual property of AqT™ to better service its partners.The driving motivation for the new division is to simplify the intellectual property and licensing [...]

Read More »


CellMosaic, Inc. received Notice of Allowance for Another Patent on NeIon™ molecules

Woburn, MA, Nov. 7, 2016 – CellMosaic announces today that the United States Patent and Trademark Office (USPTO) issued a formal Notice of Allowance for the second patent on its proprietary bio-analytical platform technology for specialty diagnostic use (Application No. 15/136,920 entitled “Trifluoroborate Mass Spectrometric Tags”). The granted patent provides intellectual property protection for a broad range of compounds and [...]

Read More »


CellMosaic, Inc. received Notice of Allowance for AqueaTether™ (AqT™) molecules.

Woburn, MA, Aug. 3, 2016 – CellMosaic announced today that the United States Patent and Trademark Office (USPTO) issued a formal Notice of Allowance for another patent on AqueaTether (AqT™) molecules (Application No. 14/156,224 entitled “Novel crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof”). Upon issuance, the patent will provide intellectual property protection for a broad range of [...]

Read More »